UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001205
Receipt number R000001470
Scientific Title Phase II study of weekly paclitaxel (wP) followed by doxorubicin plus paclitaxel (AP) as neo-adjuvant chemotherapy for triple negative Breast Cancer (WePAP)
Date of disclosure of the study information 2008/06/21
Last modified on 2018/12/18 19:53:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of weekly paclitaxel (wP) followed by doxorubicin plus paclitaxel (AP) as neo-adjuvant chemotherapy for triple negative Breast Cancer (WePAP)

Acronym

Phase II study of weekly paclitaxel (wP) followed by doxorubicin plus paclitaxel (AP) as neo-adjuvant chemotherapy for triple negative Breast Cancer (WePAP)

Scientific Title

Phase II study of weekly paclitaxel (wP) followed by doxorubicin plus paclitaxel (AP) as neo-adjuvant chemotherapy for triple negative Breast Cancer (WePAP)

Scientific Title:Acronym

Phase II study of weekly paclitaxel (wP) followed by doxorubicin plus paclitaxel (AP) as neo-adjuvant chemotherapy for triple negative Breast Cancer (WePAP)

Region

Japan


Condition

Condition

Primary breast cancer

Classification by specialty

Hematology and clinical oncology Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Evaluate the efficacy and the safety for the treatment of weekly paclitaxel (wPTX) followed by doxorubicin(ADM) plus paclitaxel in neo-adjuvant chemotherapy for Breast Cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Pathological complete response; pCR rate

Key secondary outcomes

Clinical response rate
Disease free survival
Overall survival
Breast conserving rate
Treatment compliance
Biomarkers


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

12 cycles of wPTX followed by 4 cycles of ADM+PTX (AP)
PTX 80mg/m2 12 cycles
1) day1; PTX 80mg/m2

after completion wPTX, day22 would be day1 and followed by AP 4 cycles
(q3weeks)
1) day1; ADM 50mg/m2
2) day1; PTX 150mg/m2

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

1)Histologically confirmed primary breast cancer
2)Tumor diamiter >2cm or Node positive
3) No prior chemotherapy for breast cancer
4) Age >20 y
5)ECOG PS 0-1
6)Hormone receptor negative;
ER(-) and PgR(-), less than 10% by immunohistochemistry
7)HER2 negative (<1 by HercepTest, if 2+ by HercepTest, Signal ratio <2.0 by FISH)
8) Written informed consent
9) No operation for breast cancer
10) Adequate main organ functions

Key exclusion criteria

1)Severe complication
2)Inflammatory breast caner and male breast cancer
3)Ischemic heart disease or arrhythmia which needs medical treatment (history of myocardial infarction occured within 6 months)
4)Uncontrolled diabetes
5)Suspicious of infection
6)History of serious hypersensitivity or history of allergic reaction to cremophor EL (polyoxyethylated castor oil) or polysorbate
7)During pregnancy or lactation
8)Patient judged inappropriate by physicians

Target sample size

63


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toshio Tabei

Organization

Saitama Cancer Center

Division name

Breast Medical Oncology

Zip code


Address

818 Ina-machi oaza komuro, Kita-adachi-gun, Saitama, 362-0806, Japan

TEL

048-722-1111

Email

toshikai@sbccsg.org


Public contact

Name of contact person

1st name
Middle name
Last name Toshihiro Kai

Organization

Saitama Breast Cancer Clinical Study Group (SBCCSG)

Division name

Secretariat Division (Shintoshin Ladies' MammoClinic)

Zip code


Address

3F Capital building, 4-261-1 Kishiki-cho, Omiya-ku, Saitama-shi, 330-0843, Japan

TEL

048-600-1722

Homepage URL

http://www.sbccsg.org/

Email

toshikai@sbccsg.org


Sponsor or person

Institute

Saitama Breast Cancer Clinical Study Group (SBCCSG)

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 06 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2008 Year 04 Month 07 Day

Date of IRB


Anticipated trial start date

2008 Year 06 Month 01 Day

Last follow-up date

2019 Year 04 Month 01 Day

Date of closure to data entry

2019 Year 06 Month 01 Day

Date trial data considered complete

2019 Year 08 Month 01 Day

Date analysis concluded

2020 Year 03 Month 30 Day


Other

Other related information



Management information

Registered date

2008 Year 06 Month 20 Day

Last modified on

2018 Year 12 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001470


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name